Professional
Added to YB: 2025-11-03
Pitch date: 2025-09-30
ASND [neutral]
Ascendis Pharma A/S
+22.3%
current return
Author Info
No bio for this author
Company Info
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Market Cap
$12.9B
Pitch Price
$199.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
-719.95
P/E
25.89
EV/Sales
15.30
Sector
Biotechnology
Category
growth
Artisan Global Discovery Fund Portfolio Holding: Ascendis Pharma A/S
ASND (holding update): Biotech w/ proprietary TransCon platform for sustained drug release. Yorvipath (1st hormone replacement for adult hypoparathyroidism) exceeding expectations - €103M Q2 2025 revenue (2x prior quarter), 3,100+ patients, 1,500 US prescribers. Strong uptake validates platform & pipeline.
Read full article (1 min)